King's Thrombosis Centre have published an article in CIRCULATION describing the development of a robust pharmacokinetic model of enoxaparin in pregnant women. At each monthly clinic visit, participants provided blood samples for assessment of anti-factor Xa activity in plasma at three time points—trough (the lowest concentration before the next dose), and 1 h and 3 h after enoxaparin injection. One hundred and twenty three patients contributed 795 anti-Xa activities for the modelling. Both enoxaparin clearance and volume of distribution were increased during pregnancy and the findings provide evidence for prescribing once daily enoxaparin for the treatment of antenatal VTE. The conclusion is that national and international guideline recommendations for enoxaparin dosing in pregnancy should be re-considered.


Access the article here

King's Thrombosis Centre have published an article in CHEST evaluating the impact of compulsory VTE risk assessment on the incidence of hospital-associated VTE. A significant reduction in the incidence of HAT was observed following sustained achievement of 90% risk assessment (RR 0.88, 95% CI 0.74 - 0.98; P=0.014). The article entitled "Comprehensive venous thromboembolism prevention programme incorporating mandatory risk assessment reduces the incidence of hospital-associated thrombosis" can be accessed here

King's Thrombosis Centre have published an article in the British Journal of Haematology evaluating the early predictors of post-thrombotic syndrome. The article entitled "Presenting D-dimer and early symptom severity are independent predictors for post-thrombotic syndrome following a first deep vein thrombosis" can be accessed here.

The project is being led by Dr Jig Patel, Senior Lecturer, Institute of Pharmaceutical Science at King's College London.

Page 33 of 33